Uttervall K, et al. - Through a retrospective analysis of 681 participants with multiple myeloma (MM) treated with bortezomib, lenalidomide, and dexamethasone (VRD) and bortezomib, cyclophosphamide and dexamethasone (VCD) in the first line, both with and without subsequent high dose treatment (HDT) and autologous stem cell transplantation, the researchers head-to-head contrasted the effects of VCD and VRD. In comparison to VCD in the entire VRD group and in the non-HDT group, the overall response rate was greater with VRD. More prolonged progression-free survival with VRD as that of the entire VRD group, the non-HDT group, and the HDT group was recognized at 18 months. Also, for VRD-treated patients, overall survival at 18 months was better in the whole VRD group. Hence, in MM patients with or without subsequent HDT, better responses and longer PFS as compared to VCD were ascertained.